Last reviewed · How we verify
LY03017
At a glance
| Generic name | LY03017 |
|---|---|
| Also known as | LPM526000133 Fumarate Capsules |
| Sponsor | Luye Pharma Group Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017 (PHASE1)
- Effect of Food and Age on the Pharmacokinetics of LY03017 (PHASE1)
- A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY03017 CI brief — competitive landscape report
- LY03017 updates RSS · CI watch RSS
- Luye Pharma Group Ltd. portfolio CI